New whitepaper outlines practical framework for strengthening application performance, availability and security across emerging Asia-Pacific markets

SINGAPORE and KUALA LUMPUR, Malaysia, March 10, 2026 /PRNewswire/ — Progress Software Corporation (Nasdaq: PRGS) today emphasized the growing strategic importance of load balancing in ensuring application performance, high availability and cybersecurity resilience across Asia-Pacific (APAC), as digital transformation accelerates throughout emerging markets.

Across APAC, digital adoption continues to expand rapidly. According to the World Bank Group Digital Progress and Trends Report 2023, the share of firms investing in digital solutions increased from 13% to 54% between 2020 and 2022, reflecting a significant shift toward digital banking, e-commerce platforms, government digital services and cloud-based enterprise systems^[1]. As organizations modernize infrastructure and migrate mission-critical workloads online, expectations around uptime, application performance and security have intensified.

Recent data further underscores these operational pressures. Cloud Outage Statistics for 2025–2026 from DataStackHub indicate that 63% of major cloud disruptions occur during peak traffic or system change windows^[2]. Meanwhile, Downdetector and MalaysianWireless report that leading digital outages in Asia Pacific have generated hundreds of thousands of user reports per incident, demonstrating the scale of business and consumer impact during service interruptions^[3].

Together, these trends signal a structural shift: digital services are no longer supplementary channels—they are operational backbones. As a result, load balancing has evolved from a purely technical networking function into a mission-critical component of digital infrastructure strategy.

“Organizations across APAC are scaling digital services into hybrid and multi-cloud environments, often under cost and resource constraints,” said John Yang, Vice President, Sales, Progress APJ, Progress Software. “Load balancing now plays a central role in protecting uptime, optimizing performance and mitigating security risk at the application layer.”

Converging Forces Reshaping Infrastructure Strategy

Three major forces are redefining application delivery architecture across Asia Pacific:

Digital Acceleration
Financial services, telecommunications, public sector agencies and e-commerce platforms are rapidly digitizing operations. Traffic volumes are increasingly influenced by mobile-first adoption, regional expansion and marketing-driven demand spikes.

Hybrid and Multi-Cloud Complexity
Few enterprises operate exclusively on-premises or fully in a single cloud environment. Applications frequently span private data centers, public cloud infrastructure and edge locations. Ensuring consistent performance and availability across these distributed environments requires intelligent traffic management.

Operational and Cost Efficiency Pressures
IT teams across emerging markets must scale infrastructure while optimizing capital and operational expenditure. Overprovisioning hardware to guard against peak traffic is no longer economically viable.

Without automated traffic distribution and real-time failover mechanisms, organizations risk slowdowns, downtime and degraded user experience—impacting revenue, customer trust and regulatory standing.

Load Balancing as a Strategic Control Layer

Modern load balancing solutions serve as a strategic control point within application delivery architecture. Beyond simply distributing traffic across servers, advanced load balancing capabilities enable:

• Real-time traffic optimization during high-demand events
• Automatic rerouting to maintain business continuity during outages
• Centralized visibility across hybrid and multi-cloud environments
• Enhanced application-layer security and threat mitigation
• Scalable infrastructure aligned with actual usage patterns

By intelligently managing traffic flows, organizations can improve digital experience performance, reduce latency, and strengthen cybersecurity posture—while maintaining cost discipline.

For emerging APAC markets, this balance between resilience and affordability is critical to sustaining digital growth.

New Whitepaper: “Load Balancing Made Simple for Emerging Markets”

To support IT leaders navigating these challenges, Progress has released a new whitepaper titled “Load Balancing Made Simple for Emerging Markets.”

The whitepaper provides a structured, step-by-step framework for strengthening application performance, availability and security without requiring a full-scale infrastructure overhaul. Rather than undertaking disruptive transformation initiatives, organizations can begin by modernizing one critical workload and expanding progressively.

Key areas covered in the guide include:

• Designing resilient hybrid infrastructure architectures
• Improving application uptime and disaster recovery readiness
• Optimizing performance during traffic spikes and peak demand windows
• Enhancing application-layer security against evolving cyber threats
• Reducing operational complexity through automation and centralized management

By adopting a pragmatic modernization path, organizations can better align infrastructure investment with long-term digital strategy, while maintaining flexibility to scale.

As APAC economies continue to digitalize across banking, government, healthcare, education and retail sectors, application delivery infrastructure will remain foundational to business continuity and digital competitiveness.

The full whitepaper is available for download at:
https://kemptechnologies.com/resources/whitepaper/load-balancing-made-simple-for-emerging-markets?utm_medium=content-paid&utm_source=cision&utm_campaign=lm_apj_wp_PRwire

Key References

About Progress Software

Progress Software (Nasdaq: PRGS) empowers organizations to achieve transformational success in the face of disruptive change. Our software enables our customers to develop, deploy and manage responsible AI-powered applications and personalized digital experiences with agility and ease. Businesses of all sizes get a trusted provider in Progress, with the products, expertise and vision they need to turn AI disruption into a competitive advantage. Millions of developers and technologists at hundreds of thousands of organizations depend on Progress every day. Learn more at www.progress.com. 

Building on the acquisition of Illumex by NVIDIA, the firm validates its Seed-to-Exit thesis and reinforces its mission to bridge Asian capital with world-class DeepTech.

TAIPEI, March 10, 2026 /PRNewswire/ — Cardumen Capital, a leading European DeepTech venture capital firm, today marks a pivotal milestone in its international momentum following the acquisition of its portfolio company, Illumex, by NVIDIA—a transaction reported by international media to be valued at $75 million. This landmark exit further solidifies the firm’s strategic presence in the Asia-Pacific region and cements its 2019 vintage fund’s position as a leading performer within its vintage cohort.

A Seed-to-Exit Success Story 

Cardumen Capital was Illumex’s first investor and led its 2021 seed round, supporting the company from inception through to exit. General Partners Gonzalo Martínez de Azagra and Igor de la Sota identified the startup’s potential at the seed stage, guiding it toward this landmark milestone.

“This acquisition validates our DeepTech thesis,” said Gonzalo Martínez de Azagra. “By backing visionary founders early, we demonstrate our ability to identify the core building blocks of the AI era.”

Igor de la Sota added: “The success of the Illumex exit underscores the global demand for robust data infrastructure in the age of Generative AI. We are proud to have supported the team from day one in building a platform that now sits at the heart of the world’s AI computing network.”

Strengthening the Bridge to Asia-Pacific 

Illumex joining NVIDIA serves as a powerful catalyst for Cardumen Capital’s mission in Asia. Led by Taipei-based APAC Venture Partner Stan Yu, a serial entrepreneur turned venture capitalist, the firm is intensifying its efforts to bridge Asian strategic capital with world-class innovation hubs in Europe, Israel, and global DeepTech ecosystems.

“Building on this milestone exit to NVIDIA, we are seeing unprecedented momentum for our strategy in the APAC region,” said Stan Yu. “The journey of Illumex proves the caliber of opportunities we bring to our partners. From our base in Asia, we are uniquely positioned to facilitate these high-stakes connections, ensuring that Asian institutional capital has exclusive access to the next wave of transformative DeepTech and frontier innovations.”

As a pioneering venture capital firm with a dedicated partner presence in Taiwan bridging the EMEA tech ecosystem, Cardumen Capital is uniquely positioned to drive cross-border synergies and deliver the performance expected by the institutional investment landscape in Asia.

About Cardumen Capital

Cardumen Capital, a leading global venture capital firm supervised by the CNMV (Spanish Securities Market Commission), was founded in 2018 by Gonzalo Martínez de Azagra and Igor de la Sota. With over 15 years of investment experience and a presence across Europe, the Middle East, and Asia, the firm specializes in investing in private market companies and funds, supporting innovation, disruptive technologies, and long-term value creation.

Backed by leading institutional investors, corporations, and family offices, Cardumen Capital focuses on generating sustainable long-term returns through its specialized DeepTech investment strategies and a demonstrated track record of connecting strategic capital with the global innovation frontier.

Website
LinkedIn

Building Momentum for Continued Growth

• With a strong foundation built over four decades, the company is focused on long-term growth
• The company will allocate strategic resources to next-generation technologies

SEOUL, South Korea, March 10, 2026 /PRNewswire/ — Hanon Systems, a leading global automotive thermal management supplier and subsidiary of Hankook & Company Group proudly celebrates its 40th anniversary, marking four decades to engineering excellence, continued technological innovation, and trusted partnership across the global automotive industry.

As part of the celebration, the company introduced its anniversary logo “40 Years Forward.” The logo reflects the company’s commitment to building on its 40-year legacy while accelerating its transformation in the rapidly evolving thermal energy management industry, signaling pride in past achievements and a strong focus on the future.

As part of its long-term strategy, Hanon Systems plans to gradually expand its business scope. Leveraging its proven expertise in automotive thermal management, the company aims to apply its high-efficiency thermal solutions to other sectors, including data center cooling and other key infrastructure industries. In addition, the company also intends to strengthen its position in the global aftermarket.

“The dedication of our employees, and their continued focus on quality and innovation have been the foundation of Hanon Systems’ growth over the past four decades,” said Soo-Il Lee, President and CEO of Hanon Systems. “Our 40th anniversary is not only a celebration of our history, but a commitment to disciplined execution, financial stability, and sustainable long-term growth.”

Looking forward, Hanon Systems will continue to enhance its operational efficiency and allocate strategic resources toward next-generation technologies. The company aims to evolve further as a specialized, cross-industry thermal management solutions provider.

To celebrate this milestone, the company will honor employees across its global locations in appreciation of their decades of dedication and commitment.

About Hanon Systems

Hanon Systems, founded in 1986, is a global leader in thermal management solutions. In January 2025, it became a subsidiary of Hankook & Company Group. Its offering includes a wide range of solutions in the areas of heating, ventilation and air conditioning, powertrain cooling, compressor, fluid transport, and electronics and fluid pressure. The company currently operates 50 manufacturing sites and three regional innovation centers and employs more than 20,000 people across 21 countries. To learn more, visit hanonsystems.com.

Follow Hanon Systems:

LinkedIn: https://www.linkedin.com/company/hanonsystems
YouTube: https://www.youtube.com/channel/UC6bSZ7NMg7LPhXDyTOMwebQ/feed

– Providing Real-Time Policy and Tech Insights for the $1 Trillion Foreign Investors

• Real-time English coverage of K-industry and policy news expands information access for global readers
• Expansion to global news platforms including Google News strengthens overseas reach of Korea’s digital industry news

SEOUL, South Korea, March 10, 2026 /PRNewswire/ — DigitalToday, a Korean technology news outlet, has officially launched an English-language news service powered by an AI-based real-time automated translation system, providing global readers with direct access to news about Korea’s digital industry.

The service directly targets international audiences interested in Korea’s IT, industry, and policy developments. It was introduced to deliver information about Korea’s digital sector more quickly to overseas readers who previously faced language barriers when accessing such content. Through a system that automatically generates English versions simultaneously with article publication, global readers can now follow major developments in Korea’s digital industry in real time.

DigitalToday’s English news service (digitaltoday.co.kr/en) operates using an AI translation engine developed in-house by Hecto Group. English content is automatically generated at the same time Korean articles are published and distributed through global search engines and news platforms. Chinese and Japanese versions are scheduled to be introduced sequentially, with additional language expansions also under consideration.

Global interest in Korea’s digital industry—including its startup ecosystem, artificial intelligence sector, semiconductor industry, and platform businesses—has grown significantly in recent years. As technology policy and industrial strategies increasingly influence global supply chains and investment flows, demand for information on Korea’s digital industry trends is also rising among international investors and technology professionals.

However, there are relatively few specialized media outlets that deliver real-time English coverage of Korea’s digital industry and technology policies. Through the launch of this English news service, DigitalToday aims to provide a direct information channel enabling overseas readers to understand developments in Korea’s digital economy more quickly without relying on separate translation processes.

The launch also represents part of DigitalToday’s broader strategy to expand into global news platforms. The outlet plans to broaden its reach to international audiences through global news platforms including Google News, as well as RSS feeds and social media channels. In an environment where news consumption is no longer limited by national borders or languages, DigitalToday is working to build a media ecosystem that connects with readers worldwide through multilingual content generated simultaneously with article production.

The initiative is also meaningful in terms of global information accessibility. Foreign investors currently hold approximately $1 trillion worth of listed securities in Korea’s capital market, reflecting strong global interest. Despite this, English-language channels that allow global audiences to monitor Korea’s industry and policy developments in real time have remained limited. DigitalToday aims to help global investors and industry stakeholders more easily track developments in Korea’s digital sector through this English news service.

A DigitalToday official said, “This global news service goes beyond simple translation. It represents a new news distribution model that removes language barriers in real time and connects immediately with global readers. Through AI-powered translation technology, we aim to create an environment where issues related to Korea’s digital industry and technology policy can be consumed simultaneously in the global market.”

Meanwhile, major global media organizations are also expanding their international readership through English-based global news services. Japan’s Nikkei, for example, targets global audiences through its English-language platform Nikkei Asia, while The New York Times utilizes generative AI across various areas including editorial tools, summarization systems, and content recommendations.

Through the expansion of its global multilingual services, DigitalToday aims to accelerate the global dissemination of K-digital industry content, increase international visibility of technology and policy news, and demonstrate practical applications of AI-driven news automation systems. The company plans to continue expanding as a digital news platform connecting with global readers. (End)

About DigitalToday (www.digitaltoday.co.kr):
DigitalToday is a leading Korean digital news media outlet covering ICT, industry, policy, and startups. Through data-driven reporting and technology-focused journalism, the outlet delivers rapid insights into industry developments. DigitalToday continues to pursue media innovation through AI-powered content automation and global multilingual news services.

TOKYO, March 10, 2026 /PRNewswire/ — TIER IV, the pioneering force behind open-source software for autonomous driving, has officially joined the Automotive Chiplet Program (ACP) overseen by imec, a world-leading research and innovation center in nanoelectronics and digital technologies. This partnership serves as a technical foundation for TIER IV’s multi-environment, multi-application strategy, designed to deliver scalable autonomous driving solutions across the global mobility ecosystem.

A unified strategy for the SDV era

As the industry pivots toward software-defined vehicles (SDVs), the decoupling of hardware and software has become a competitive necessity. TIER IV is addressing this through two key pillars:

• Multi-environment: Ensures compatibility with vehicles from automakers, Autoware*, open-source software for autonomous driving, and hardware architectures, including system-on-chips and sensors.
• Multi-application: Supports various use cases through system development and integration, embedded vehicles, reference designs, and customary services.

Chiplet technology is an approach to building semiconductors by combining various chips with specific functions. By participating in the ACP, TIER IV is advocating for chiplet-based architectures that allow these diverse software applications to run efficiently across different silicon platforms. This modularity ensures that vehicle manufacturers can utilize the best-in-class processing for their specific needs without being locked into a single proprietary hardware vendor.

From LiDAR processing to AI acceleration

A critical component of this collaboration is the co-design of specialized hardware accelerators. TIER IV has already achieved a major milestone by finalizing the development of a LiDAR accelerator, designed for high-speed 3D point-cloud processing.

Building on this success, TIER IV is now focusing its research within the ACP on AI accelerators tailored for AI-based autonomous driving. As Autoware moves toward neural networks that handle everything from perception to planning, the hardware must evolve to support high-throughput AI workloads. Chiplet technology allows TIER IV to integrate its perception expertise directly into the system-on-chip alongside other compute tiles, ensuring the low latency and high efficiency required for future auto-grade autonomous systems.

“Our strategy is built on the principle that autonomous driving should be adaptable to any platform and any use case,” said Shinpei Kato, founder and CEO of TIER IV. “Joining imec’s ACP allows us to harmonize open-source software with silicon based on open standards. Regardless of the underlying computing architecture, our goal is to ensure that Autoware and our AI-based models deliver peak performance through optimized chiplet designs.”

“We’re delighted to welcome TIER IV to imec’s ACP,” said Bart Placke, VP imec Automotive. “As the automotive industry transitions toward chiplet architectures, it is increasingly clear that this shift cannot happen in isolation. That’s why ACP brings the ecosystem together in a pre-competitive effort to align on standards and validate approaches that meet automotive-grade requirements. With TIER IV on board for this program, we can combine our semiconductor and system integration expertise with their leading capabilities in autonomous driving software and reference platforms. Together, we aim to accelerate the maturation of chiplet-based architectures that will underpin the next generation of safe, reliable, scalable and energy-efficient autonomous mobility.”

Building the future of open hardware

TIER IV is working with a global ecosystem of industry leaders to define the pre-competitive standards for automotive chiplets through the ACP. This collaborative effort ensures that the Autoware Foundation’s Open AD Kit and TIER IV’s Co-MLOps platform remain at the cutting edge of semiconductor innovation. By championing an open, interoperable chiplet ecosystem, TIER IV is fostering a transparent supply chain that accelerates the path to safe and scalable autonomous driving worldwide.

*Autoware is a registered trademark of the Autoware Foundation.

About TIER IV

TIER IV stands at the forefront of deep tech innovation, pioneering Autoware, open-source software for autonomous driving. With a comprehensive suite of platforms and services built around Autoware, TIER IV provides everything from software development and vehicle procurement to operational support. Through the Autoware ecosystem, TIER IV works with partners worldwide to shape the future of intelligent vehicles with open-source software, aiming to create mobility that is safer, more sustainable, and accessible to all.

Media contact
pr@tier4.jp

Built alongside auditors and industry experts, the new solution sets a new benchmark for financial transparency, compliance, and operational scale for short-term rental property managers across Australia and New Zealand.

SYDNEY, March 10, 2026 /PRNewswire/ — Guesty, the global property management software leader for the short-term rental industry, today announced the launch of its fully compliant trust accounting solution for property managers across Australia and New Zealand (ANZ). Built to align with the region’s most demanding regulatory framework, Queensland trust accounting regulations, the new infrastructure sets a new benchmark for financial compliance and operational confidence in the short-term rental industry.

Guesty Launches Fully Compliant Trust Accounting Aligned with Australia’s Highest Regulatory Standards

Trust accounting in Australia is among the most rigorous financial frameworks property managers operate within. For short-term rental operators managing growing portfolios, maintaining compliance while scaling operations has long been a complex and resource-intensive challenge.

Guesty’s new trust accounting solution was developed to address that challenge head-on.

Built in collaboration with one of Australia’s leading trust accounting auditing firms and backed by nearly 30 years of local trust accounting expertise, the solution combines deep regulatory knowledge with Guesty’s global product development capabilities to deliver the most advanced trust accounting infrastructure available to short-term rental property managers in the region.

Unlike traditional accounting systems that operate separately from operational platforms, Guesty’s trust accounting is built directly into its industry-leading property management software, allowing property managers to manage financial operations, owner reporting, and portfolio performance within a single system.

• Full compliance aligned with Queensland’s rigorous trust accounting regulatory standards
• Transparent financial visibility across properties, owners, and portfolios
• Automated workflows designed to reduce manual reconciliation and reporting complexity
• Integrated accounting infrastructure built directly into Guesty’s best-in-class PMS
• Local expert support from an Australian-based trust accounting team

Together, these capabilities allow property managers across Australia and New Zealand to manage financial operations with confidence while continuing to scale their businesses.

“This launch represents a major milestone for the short-term rental industry in Australia and New Zealand,” said Yoav Tourel, Managing Director, APAC at Guesty. “Trust accounting has traditionally been one of the most complex and stressful parts of operating a property management business in the region. By working alongside auditors and industry experts, we’ve built a solution that meets the highest regulatory standards while making financial operations significantly easier for operators.”

With the introduction of fully compliant trust accounting aligned to Australia’s most demanding regulatory framework, Guesty continues to expand the infrastructure supporting professional property managers as the short-term rental industry grows and matures globally.

About Guesty

Guesty, the end-to-end platform built for the short-term rental industry, empowering property managers and hosts to grow smarter, scale faster, and deliver standout guest experiences. With the largest R&D team in the industry, Guesty is the engine inside more than 500,000 properties across 100+ countries, powering more properties, more platforms, and more bookings across major OTAs like Airbnb, Vrbo, Booking.com, Expedia, Tripadvisor, Hopper, Google Travel, and Homes & Villas by Marriott. Backed by $410 million in funding from KKR, Apax Digital Fund, Inovia Capital, DFO Management (formerly MSD Capital), Sixth Street Growth, Viola Growth, and Flashpoint, Guesty’s global team is building the future of the short-term rental industry under one roof, for every platform, every property, and every tool.

Guesty’s platform is designed to deliver: maximum occupancy, maximum revenue, maximum ease, and the highest guest and owner satisfaction. Learn more at guesty.com.

Contact details

Michelle Chiera
Head of Communications & PR
Michelle.Chiera@guesty.com

• Webcast and conference call to be held today, Tuesday March 10 at 9:30 a.m. AEDT (Monday March 9 at 6:30 p.m. EDT). Investors can register at the following link: https://s1.c-conf.com/diamondpass/10053620-ju7y6t.html

MELBOURNE, Australia and INDIANAPOLIS, March 10, 2026 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that Part 1 of the ProstACT Global Phase 3 study, the safety and dosimetry lead-in for its therapeutic candidate – TLX591-Tx (lutetium-177 (¹⁷⁷Lu) rosopatamab tetraxetan) – has achieved its primary objectives, demonstrating an acceptable safety and tolerability profile with no new safety signals observed.

Key findings include:

• Tolerability profile supported by dosimetry and low-grade non-hematologic events.
• Lesion dosimetry indicates no difference in absorbed dose profile across cohorts.
• No adverse drug-drug interactions observed in TLX591-Tx combinations.
• Hematologic events are in line with expectations and transient and manageable, with similar rates of recovery across all patient cohorts.
• The results from Part 1 are consistent with prior clinical studies of this first-in-class lutetium radio antibody-drug conjugate (rADC) therapy.

Part 1 of the study confirmed the safety profile, biodistribution and dosimetry of TLX591-Tx administered in two doses, 14 days apart, in combination with one of three standard of care (SOC) therapies: abiraterone, enzalutamide or docetaxel. The patient population comprised prostate-specific membrane antigen (PSMA) positive metastatic castration resistant prostate cancer (mCRPC) patients previously treated with one androgen receptor pathway inhibitor (ARPI).

ProstACT Global is a differentiated Phase 3 trial comparing PSMA-targeted ¹⁷⁷Lu-rADC therapy administered with SOC versus SOC alone, a trial design intended to reflect current global clinical practice^[1]. Telix has already advanced the study into Part 2 – a 2:1 randomized treatment expansion – in jurisdictions where the clinical trial has obtained approval from health authorities^[2]. Part 1 data will be presented to the United States (U.S.) Food and Drug Administration (FDA) to seek an Investigational New Drug (IND) amendment to progress Part 2 in the U.S.

Neeraj Agarwal, MD, Professor of Medicine and Presidential Endowed Chair of Cancer Research at Huntsman Cancer Institute, Salt Lake City, and ProstACT Global Principal Investigator and Steering Committee member, commented, “These results reinforce the feasibility of integrating TLX591-Tx with current standard of care therapies for mCRPC, including ARPIs such as enzalutamide or abiraterone, or docetaxel. Hematologic events align with those typically seen in this patient population and therapeutic class, and these cases resolved quickly. The dosimetry profile, along with the low-grade nature of non-hematologic adverse events, further supports the tolerability profile of this investigational therapy.”

David N. Cade, MD, Group Chief Medical Officer, Telix added, “Despite advances in clinical practice, men with advanced prostate cancer still need improved first and second line treatment options. These results build on prior findings and highlight the potential for TLX591-Tx in combination with contemporary standard of care, to become a new first-line option for patients facing this aggressive disease. We are encouraged by the data and look forward to engaging with the FDA at the earliest opportunity, while continuing to advance enrollment in Part 2 in regions where clinical trial initiation has already been approved.”

Summary results

ProstACT Global Part 1 dosed 36 patients, allocated across 3 cohorts:

• Cohort 1 (11 patients): TLX591-Tx + enzalutamide.
• Cohort 2 (11 patients): TLX591-Tx + abiraterone.
• Cohort 3 (14 patients): TLX591-Tx followed by docetaxel.

Safety and tolerability

• An acceptable safety profile was observed across combination cohorts and tolerability of TLX591-Tx was consistent with prior studies.  
• All 36 patients received both doses of TLX591-Tx per protocol, no new safety signals were observed.
• Almost all treatment-emergent non-hematologic events were Grade 1 or Grade 2. The most prevalent were fatigue (53%), nausea (28%) and dry mouth (25%).
• Hematologic events were transient and manageable.
• Grade 3 thrombocytopenia (14%) and neutropenia (22%), and Grade 4 thrombocytopenia (31%) and neutropenia (25%) events were in line with the profile expected for this class of therapy and extent of disease.

Dosimetry and biodistribution

• Radiation exposure to key organs was well below established safety limits^[3].
• Limited dose to salivary glands and kidneys.
• Lesion dosimetry demonstrated uptake across tumor sites and across all cohorts.
• Pharmacokinetics demonstrated sustained activity at 15 days, corroborated by imaging which demonstrated prolonged tumor retention.
• No evidence of drug-drug interactions impacting TLX591-Tx targeting, distribution or clearance.

About ProstACT Global

ProstACT Global (ClinicalTrials.gov ID: NCT06520345) is an international, multicenter trial in two parts: Part 1, safety and dosimetry lead-in with 36 patients (complete); and Part 2, 2:1 randomized global expansion with an overall target enrollment of approximately 490 patients. Eligible patients must have confirmed progressive mCRPC assessed with a ⁶⁸Ga-PSMA-11 PET^[4] imaging agent (such as Illuccix®, kit for the preparation of gallium-68 (⁶⁸Ga) gozetotide injection, or Gozellix®, kit for the preparation of gallium-68 (⁶⁸Ga) gozetotide injection) following prior treatment with one ARPI.

The antibody approach demonstrates different targeting and pharmacology to that observed in other PSMA-targeted small molecule radioligand therapies (RLT). In contrast to these therapies^[5], collective long-term follow-up of patients administered with TLX591-Tx has not observed significant acute or delayed kidney toxicity, as the agent is primarily cleared through the liver, a comparatively radioresistant organ, instead of the kidneys^[6]. Due to its large molecular weight, TLX591-Tx also demonstrates minimal salivary and lacrimal gland uptake, reducing dry mouth and dry eyes, common adverse effects of existing PSMA-targeted RLTs^[7].

Additional information on the Phase 3 ProstACT Global study can be found at: https://telixpharma.com/prostact/

About Telix Pharmaceuticals Limited

Telix is a global biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies, with the goal to address significant unmet medical needs in oncology and rare diseases. With international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan, Telix is headquartered in Melbourne, Australia. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Telix’s Precision Medicine franchise includes llluccix®, approved in multiple markets globally, and Gozellix®, approved by the U.S. FDA^[8]. TLX591-Tx has not received a marketing authorization in any jurisdiction.

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.

This announcement has been authorized for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board. 

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements. 

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including the planned NDA resubmission for TLX101-Px and the planned BLA resubmission for TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2026 Telix Pharmaceuticals Limited. All rights reserved.

^[1] National Comprehensive Cancer Network® Clinical Practice Guidelines in Oncology for Prostate Cancer V3.2026; Narayan et al. Clin Genitourin Cancer. 2024.
^[2] Part 2 is enrolling in Australia, New Zealand, and Canada, and has also received regulatory approval to commence in China, Singapore, South Korea, Türkiye, and the United Kingdom.
^[3] Wahl et al. J Nucl Med. 2021; Emami et al. Int J Radiat Oncol Biol Phys. 1991.
^[4] Positron emission tomography.
^[5] Tagawa et al. Curr Oncol Rep. 2021; Steinhelfer et al. J Nucl Med. 2024.
^[6] Tagawa et al. Cancer. 2019.
^[7] Pepin et al. Pract Radiat Oncol. 2025. 
^[8] Telix ASX disclosure March 21, 2025.